Sign up for updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Your data is valuable and we will never sell or share it without your permission. By signing up to receive notifications from us, you agree to our Privacy policy.

Investor Relations

Recent News

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

Biovaxys Announces Planned Private Placement

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Director made an order under paragraphs 2 and 2.1 of subsection 127(1)

BioVaxys Completes the Acquisition of All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT

BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT

Featured Stories

BioVaxys Announces Sale Of TAET Software Co.

Aliquam Autem Perspiciatis

Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT

BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition

BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare

BioVaxys Announces Revocation of Cease Trade Order and Expansion of Cancer Vaccine Platform Patent Portfolio

BioVaxys and The Ohio State University Extend Research Collaboration

BioVaxys Announces Management Change